We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

LINX Reflux Management System Clinical Study Protocol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00776997
Recruitment Status : Completed
First Posted : October 22, 2008
Results First Posted : November 13, 2013
Last Update Posted : May 4, 2018
Information provided by (Responsible Party):
Torax Medical Incorporated

Brief Summary:
The purpose of the study is to evaluate the safety and effectiveness of the LINX Reflux Management System in the treatment of Gastroesophageal Reflux Disease (GERD).

Condition or disease Intervention/treatment Phase
Gastroesophageal Reflux Device: Magnetic Sphincter Augmentation Not Applicable

Detailed Description:

At present, the primary alternative for GERD patients with an incomplete symptomatic response to proton-pump inhibitors (PPIs) is laparoscopic Nissen fundoplication. This surgical procedure continues to be the prevalent non-medical treatment option for GERD patients, despite several important limitations. First, it is a very traumatic procedure, requiring portions of the stomach to be dissected and then wrapped around the tubular esophagus, creating permanent anatomic alterations. Secondly, it can create significant side effects, such as gas bloat syndrome, the inability to belch and the inability to vomit.

The intent of the LINX System is to allow a surgeon, using existing laparoscopic techniques and instruments, to augment a weak LES and restore the defective barrier at the gastroesophageal junction (GEJ). This defect of the GEJ is the source of abnormal reflux. The LINX device is an expandable string of individual titanium beads with magnetic cores. The device is laparoscopically placed as a ring around the lower esophageal sphincter. The magnetic attraction of the beads augments the esophageal sphincter's ability to resist gastric pressures that cause reflux. At rest, the LINX device encircles the sphincter with each bead resting against an adjacent bead, to avoid compression of the tubular esophagus. When swallowing, higher pressures are created, allowing the magnetic bond between beads to break, and the LINX implant to expand radially. This serves to preserve swallow and other physiologic functions, such as belching and vomiting, and avoids the side effect of post-prandial bloating. The device can be placed with minimal dissection, preserving anatomy, and is also removable, if necessary. This provides important benefits as it preserves the native anatomy, unlike the Nissen procedure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: LINX Reflux Management System Clinical Study Protocol
Study Start Date : November 2008
Actual Primary Completion Date : December 2010
Actual Study Completion Date : September 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: GERD

Arm Intervention/treatment
Magnetic Sphincter Augmentation
Single-arm study: all subjects were treated with magnetic sphincter augmentation. A subject's baseline measurements prior to sphincter augmentation were compared to post-sphincter augmentation measurements. Subjects served as their own control.
Device: Magnetic Sphincter Augmentation
The area of the lower esophageal sphincter (LES) is accessed using a standard laparoscopic approach. The tubular esophagus, in the area of the LES, is sized and the appropriately sized sphincter augmentation device is placed circumferentially around the esophagus in the area of the LES. After confirming proper placement, the ends of the device are secured. At this point, the implant procedure is complete, laparoscopic instruments are withdrawn and access points are closed.
Other Names:
  • LINX Reflux Management System
  • Magnetic Esophageal Sphincter

Primary Outcome Measures :
  1. Rate of Occurrence for Device and Procedure Related Serious Adverse Events (SAEs). [ Time Frame: through 24 months ]

    SAE was defined as any untoward medical occurrence, whether related to the study device or procedure or not, that meets one or more of the following criteria:

    • Results in death
    • Is life-threatening
    • Requires subject hospitalization > 24 hours
    • Requires prolongation of an existing hospitalization
    • Results in persistent or significant disability/incapacity
    • Results in fetal distress, fetal death, or a congenital anomaly or birth defect
    • Requires intervention to prevent permanent impairment or damage.

    Outcome measure reports number of subjects with reported events.

  2. Normalization of Esophageal Acid Exposure Time or Reduced Total Acid Exposure Time of at Least 50% Compared to the Subject's Baseline Measurement by Esophageal pH Testing. [ Time Frame: 12 Months ]
    The analysis cohort for the primary efficacy analysis was the treated population which includes all implanted subjects and was determined through esophageal pH testing.

Secondary Outcome Measures :
  1. At Least a 50% Reduction in Gastroesophageal Reflux Disease-Health-Related Quality of Life (GERD-HRQL) Total Score Compared to Baseline [ Time Frame: 12 months ]
  2. Average Daily Proton-pump Inhibitor (PPI) Dosage Reduced by at Least 50% Compared to Baseline [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject must be at least 18 years of age and at least the minimum Age of Majority according to applicable State or Country Law and must be less than 75 years of age, with a life expectancy > 3 years
  • Subject is a suitable surgical candidate, i.e. is able to undergo general anesthesia and laparoscopic surgery
  • Documented typical symptoms of gastroesophageal reflux disease (GERD) for longer than 6 months (regurgitation or heartburn which is defined as a burning epigastic or substernal pain which responds to acid neutralization or suppression)
  • Patient requires daily proton pump inhibitor or other anti-reflux drug therapy
  • Total Distal Ambulatory Esophageal pH must meet the following criteria: pH< 4 for ≥ 4.5% of the time Note: Subjects shall have discontinued any GERD medications for at least 7 days prior to testing.
  • Subjects with symptomatic improvement on proton-pump inhibitor (PPI) therapy demonstrated by a GERD-Health-Related Quality of Life (GERD-HRQL) score of ≤ 10 on proton-pump inhibitors and ≥ 15 off PPIs, or subjects with a ≥ 6 point improvement when comparing their on PPI and off PPI GERD-HRQL score
  • GERD symptoms, in absence of PPI therapy (minimum 7 days)
  • If the subject is of child bearing potential must have a negative pregnancy test within one week prior to implant and must agree to use effective means of birth control during the course of the study
  • Subject is willing and able to cooperate with follow-up examinations
  • Subject has been informed of the study procedures and the treatment and has signed an informed consent form

Exclusion Criteria:

  • The procedure is an emergency procedure
  • Currently being treated with another investigational drug or investigational device
  • History of gastroesophageal surgery, anti-reflux procedures, or gastroesophageal/gastric cancer
  • Any previous endoscopic anti-reflux intervention for GERD
  • Suspected or confirmed esophageal or gastric cancer
  • Any size hiatal hernia >3cm as determined by endoscopy
  • Distal esophageal motility (average of sensors 3 and 4) is less than 35 mmHg peristaltic amplitude on wet swallows or <70% (propulsive) peristaltic sequences
  • Esophagitis - Grade C or D (LA Classification)
  • Body Mass Index (BMI)>35
  • Symptoms of dysphagia more than once per week within the last 3 months.
  • Diagnosed with Scleroderma
  • Diagnosed with an esophageal motility disorder such as but not limited to Achalasia, Nutcracker Esophagus, or Diffuse Esophageal Spasm or Hypertensive LES
  • Subject has a history of or known esophageal stricture or gross esophageal anatomic abnormalities (Schatzki's ring, obstructive lesions, etc.)
  • Subject has esophageal or gastric varices
  • Subject has history of or known Barrett's esophagus
  • Cannot understand trial requirements or is unable to comply with follow-up schedule
  • Pregnant or nursing, or plans to become pregnant during the course of the study
  • Medical illness (i.e. congestive heart failure) that may cause the subject to be non-compliant with or able to meet the protocol requirements or is associated with limited life expectancy (i.e. less than 3 years)
  • Diagnosed psychiatric disorder (e.g. bipolar, schizophrenia, etc.), subjects that exhibit depression that are on appropriate medication(s) are allowable.
  • Suspected or known allergies to titanium, stainless steel, nickel or ferrous materials
  • Subject has an electrical implant or metallic, abdominal implants

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00776997

Layout table for location information
United States, California
USC Keck School of Medicine
Los Angeles, California, United States, 90033
University of California - San Diego
San Diego, California, United States, 92103
United States, Florida
Mayo Clinic
Jacksonville, Florida, United States, 32224
United States, Georgia
Phoebe Putney Memorial Hospital
Albany, Georgia, United States, 31701
United States, Minnesota
Abbott Northwestern Hospital/MNGI
Minneapolis, Minnesota, United States, 55407
United States, Missouri
Washington University - Division of Gastroenterology
Saint Louis, Missouri, United States, 63110
United States, New York
University of Rochester Medical Center
Rochester, New York, United States, 14642
United States, Ohio
The Ohio State University Medical Center / Center for Minimally Invasive Surgery
Columbus, Ohio, United States, 43210
Knox Community Hospital
Mount Vernon, Ohio, United States, 43050
United States, Oregon
Legacy Health System
Portland, Oregon, United States, 97210
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
United States, Washington
University of Washington Medical Center
Seattle, Washington, United States, 98195
United States, Wisconsin
Gundersen Lutheran Clinic
La Crosse, Wisconsin, United States, 54601
Academic Medical Center
Amsterdam, Netherlands, 1105 AZ
Sponsors and Collaborators
Torax Medical Incorporated
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Torax Medical Incorporated
ClinicalTrials.gov Identifier: NCT00776997    
Other Study ID Numbers: 1802
First Posted: October 22, 2008    Key Record Dates
Results First Posted: November 13, 2013
Last Update Posted: May 4, 2018
Last Verified: March 2018
Keywords provided by Torax Medical Incorporated:
Gastroesophageal Reflux
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases